{"id":"mw031","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of MW031 is not publicly detailed, it is being developed by Mabwell as an oncology therapeutic in Phase 3 trials. Based on the company's pipeline focus, it likely functions as an immune checkpoint inhibitor or tumor-targeting antibody designed to engage the immune system against cancer cells.","oneSentence":"MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:24.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06804590","phase":"PHASE3","title":"A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-11-16","conditions":"Postmenopausal Women Osteoporosis","enrollment":278},{"nctId":"NCT05215977","phase":"PHASE3","title":"Efficacy and Safety of MW031 in PMO Subjects","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2019-12-27","conditions":"Osteoporosis, Postmenopausal","enrollment":448},{"nctId":"NCT04798313","phase":"PHASE1","title":"Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-06-02","conditions":"Osteoporosis, Postmenopausal","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant anti-RANKL human monoclonal antibody injection"],"phase":"phase_3","status":"active","brandName":"MW031","genericName":"MW031","companyName":"Mabwell (Shanghai) Bioscience Co., Ltd.","companyId":"mabwell-shanghai-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity. Used for Oncology indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}